{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-23-000025","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.847893+00:00","generated_at":"2026-06-12T08:40:02.852332+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna Q2 net loss $1.4B, EPS -$3.62; revenue $344M (-93% YoY); FY23 sales guidance $6-8B","bullets":["Q2 revenue $344M vs $4.7B YoY; product sales $293M, down 94% due to lower COVID vaccine volume.","Net loss $1.4B vs net income $2.2B YoY; diluted EPS -$3.62 vs +$5.24.","Cost of sales $731M includes $464M inventory write-downs, $135M unutilized capacity, $75M purchase commitment losses.","Guides FY23 COVID vaccine sales $6-8B; expects ~$1B of APAs deferred to 2024; cost of sales now $3.5-4B.","RSV vaccine submitted globally for approval; Phase 3 melanoma combo trial with Merck initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-23-000025","json":"https://secwatch.observer/filing/0001682852-23-000025.json","markdown":"https://secwatch.observer/filing/0001682852-23-000025.md","text":"https://secwatch.observer/filing/0001682852-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/0001682852-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/mrna-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:40:02.852332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6986507b1b801da6e9cd235be624a9f7524ae3dd","claim":"Moderna, Inc. reported the second quarter of 2023 results: revenue $344 million, net income net loss of $1.4 billion, EPS loss per share of $3.62. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the second quarter of 2023 was $344 million, compared to $4.7 billion in the same period in 2022, mainly due to a decrease in sales of the Company’s COVID-19 vaccine.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/0001682852-23-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$344 million"},{"label":"Net income","value":"net loss of $1.4 billion"},{"label":"EPS","value":"loss per share of $3.62"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}